AUS
NZ
UK
CA
USA
IND
Highlights
- NRx Pharmaceuticals to participate in a fireside chat during the BTIG Virtual Biotechnology Conference
- Jonathan Javitt to leading medical experts in a discussion on neuroplasticity in CNS treatment
- Focus includes the use of ketamine and other compounds in addressing depression
NRx Pharmaceuticals, listed on the Nasdaq Index, operates in the central nervous system (CNS) therapeutics sector. The company continues to advance clinical research and development in psychiatric and neurological conditions, focusing on compounds that target NMDA receptors. Its lead therapeutic platforms aim to address unmet needs in serious mental health conditions, including suicidal bipolar depression and post-traumatic stress disorder (PTSD).
BTIG Virtual Biotechnology Conference
The company announced the participation and Chairman, Prof. Jonathan Javitt, MD, MPH, in an upcoming fireside chat at the BTIG Virtual Biotechnology Conference. The session is scheduled for July 30 and will include a discussion with Dr. Samuel Wilkinson of Yale School of Medicine and Dr. Thomas Shrader of BTIG.
This dialogue will focus on innovations in neuroplasticity for CNS treatment, with specific attention to the role of ketamine and other neuroplastic or psychedelic agents in managing psychiatric conditions such as depression and suicidality.
Focus on NMDA-Based Therapeutics
NRx Pharmaceuticals (NASDAQ:NRXP) is developing multiple investigational therapies built around its NMDA platform. Its key asset, NRX-101, is in clinical development for conditions including suicidal bipolar depression, chronic pain, and PTSD. The formulation has received Breakthrough Therapy Designation from the FDA, underscoring its clinical relevance.
Additionally, NRX-101 is being evaluated for use in patients with akathisia, a complex condition that commonly co-occurs with psychiatric illness. The therapy is designed as an oral compound intended to offer benefits beyond standard treatment options currently in use.
Progress Toward New Drug Applications
The company has recently initiated the filing process for a New Drug Application (NDA) for NRX-100, its intravenous ketamine formulation. This application is supported by controlled clinical trial results from studies conducted under the U.S. National Institutes of Health, along with newly shared data from French regulatory agencies.
NRx Pharmaceuticals received Fast Track Designation from the U.S. FDA for NRX-100. This designation aligns with the urgent need to develop treatments for patients in acute suicidal crises, a focus area for the company’s clinical programs.
Broader Therapeutic Applications Under Evaluation
Beyond depression and PTSD, NRx Pharmaceuticals (NASDAQ:NRXP) is exploring the role of NRX-101 as a non-opioid alternative for chronic pain. The platform is also being researched for complex urinary tract infections, indicating a diversified research pipeline targeting various CNS and pain-related disorders.
The company’s approach reflects a commitment to advancing treatments that address both psychiatric and somatic conditions through its proprietary NMDA-based strategies.
What is the focus of NRx Pharmaceuticals’ upcoming appearance at the BTIG conference?
The session will focus on neuroplasticity in CNS disorders, including the use of ketamine and similar compounds for depression, suicidality, and PTSD.
What therapies are NRx Pharmaceuticals currently developing?
The company is developing NRX-101 and NRX-100, both targeting CNS-related conditions such as suicidal depression, PTSD, and chronic pain.
Has any regulatory agency recognized NRx Pharmaceuticals’ drug candidates?
NRX-101 has been granted Breakthrough Therapy Designation, and NRX-100 has received Fast Track Designation from the U.S. FDA.
